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Background: Chemokine receptor signaling pathways are implicated in the pathobiology of renal cell carcinoma
(RCC). However, the clinical relevance of CXCR2 receptor, mediating the effects of all angiogenic chemokines,
remains unclear. SOCS (suppressor of cytokine signaling)-3 is a negative regulator of cytokine-driven responses,
contributing to interferon-α resistance commonly used to treat advanced RCC with limited information regarding
its expression in RCC.
Methods: In this study, CXCR2 and SOCS-3 were immunohistochemically investigated in 118 RCC cases in relation
to interleukin (IL)-6 and (IL)-8, their downstream transducer phosphorylated (p-)STAT-3, and VEGF expression, being
further correlated with microvascular characteristics, clinicopathological features and survival. In 30 cases
relationships with hypoxia-inducible factors, i.e. HIF-1a, p53 and NF-κΒ (p65/RelA) were also examined. Validation
of immunohistochemistry and further investigation of downstream transducers, p-JAK2 and p-c-Jun were evaluated by
Western immunoblotting in 5 cases.
Results: Both CXCR2 and IL-8 were expressed by the neoplastic cells their levels being interrelated. CXCR2 strongly
correlated with the levels of HIF-1a, p53 and p65/RelA in the neoplastic cells. Although SOCS-3 was simultaneously
expressed with p-STAT-3, its levels tended to show an inverse relationship with p-JAK-2 and p-c-Jun in Western blots
and were positively correlated with HIF-1a, p53 and p65/p65/RelA expression. Neither CXCR2 nor SOCS-3 correlated
with the extent of microvascular network. IL-8 and CXCR2 expression was associated with high grade, advanced stage
and the presence/number of metastases but only CXCR2 adversely affected survival in univariate analysis. Elevated
SOCS-3 expression was associated with progression, the presence/number of metastasis and shortened survival in both
univariate and multivariate analysis.
Conclusions: Our findings implicate SOCS-3 overexpression in RCC metastasis and biologic aggressiveness advocating
its therapeutic targeting. IL-8/CXCR2 signaling also contributes to the metastatic phenotype of RCC cells but appears of
lesser prognostic utility. Both CXCR2 and SOCS-3 appear to be related to transcription factors induced under hypoxia.
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Renal cell carcinoma (RCC) is notorious for its angiogenic
properties [1,2] and its ability to evade immunosurveillance.
Therefore, not surprisingly, current literature is replete with
studies looking into the mechanisms underlying the
angiogenic phenotype of this tumor. The vast majority
of these tumors are associated with the inactivation of
the von Hippel-Lindau (VHL) tumor suppressor gene,
which leads to the stabilization of hypoxia-inducible
factor-1α (HIF-1α) with consequent enhanced transcription
of many proangiogenic factors, such as vascular endothelial
growth factor (VEGF) [3].
Cytokines are major regulatory proteins controlling the
growth and differentiation of normal and malignant cells
and contributing to the immune system’s failure to
recognize tumor cells [4]. The pleiotropic cytokine interleu-
kin (IL)-6, in particular, is known to induce the expression
of VEGF [5], which is considered to be a major endothelial
mitogen in RCC. IL-6 is one of the most ubiquitously
deregulated cytokines in cancer, including RCC (rev. in
[6]). IL-6 signals through a cell surface type I cytokine
receptor including the signal transducing component
GP130 which activates the tyrosine kinase JAK and ultim-
ately the signal transducer and activator of transcription
(STAT)-3 [7]. The latter is activated through phosphoryl-
ation at Tyr705 also in response to growth factors and
extracellular signals [8]. Once phosphorylated, STAT-3
translocates to the nucleus where it binds to IFN-γ-
activated site-like DNA elements [9], inducing the expres-
sion of genes promoting abnormal cell cycle progression,
angiogenesis, inhibition of apoptosis, tissue invasion and
immune evasion [10].
Chemokines are small chemoattractant cytokines that
play an integral role in the pathobiology of RCC (rev. in
ref [4]). The ELR + family of CXC-chemokines to which
interleukin (IL)-8 belongs are recognized as potent pro-
moters of angiogenesis by virtue of the Glu-Leu-Arg (ELR)
motif immediately preceding their first N-terminal cysteine
residue [11]. IL-8 effects are mediated by two highly related
G-protein coupled receptors – chemokine (C-X-C motif)
receptor 1 (CXCR1) and CXCR2. CXCR2 is promiscuous
in nature since it can bind all other ELR + chemokines [12]
and constitutes the prime functional chemokine receptor
mediating endothelial cell chemotaxis in response to ligand
binding [13]. Recently, IL-8 has been identified as a con-
tributor to resistance to the anti-angiogenic agent sunitinib
in RCC [14].
The interest in the identification of up-stream regulators
of the cytokine-driven STAT activation stems from the
profound biologic consequences of uncontrolled cytokine
signaling [15]. To date, the only known inhibitors in this
regard are the suppressors of cytokine signaling (SOCS),
comprising SOCS-1–SOCS-7 and the cytokine-inducible
SH2 domain containing protein. These proteins recognizephosphorylated tyrosine residues on JAKs and/or cytokine
receptor subunits, thereby attenuating response to cyto-
kines or growth factors [16]. STAT-3 induces SOCS-3
which feeds back to negatively regulate JAK/STAT [17].
Due to their rapid induction and quick turnover, SOCS
proteins act as negative regulators of IFN-α signaling by
inhibiting the JAK/STAT pathway, thereby opposing its
proliferative and anti-apoptotic and apoptotic effect [18].
However, the function of SOCS is more complex than ori-
ginally thought since they may facilitate or suppress neo-
plastic transformation depending on cellular context [19].
In this study, we focus on the expression of CXCR2
and SOCS-3 in RCC. We chose to investigate CXCR2 and
not CXCR1 because of experimental evidence underlining
the importance of CXCR2/CXCR2 ligand in RCC biology
[20], although the clinical relevance of this axis is un-
known. Characterization of SOCS-3 expression, on the
other hand, in tissue samples of RCC has not thus far
been performed, despite its suspected involvement in
the response of RCC to IFN-α by virtue of its interaction
with JAK/STAT signaling, as alluded to [18]. First, we ana-
lyzed the relationships of CXCR2 with the proangiogenic
cytokines and of SOCS-3 with p-STAT-3 in a series of
RCC patients. Immunohistochemistry was validated by
Western immunoblotting in 5 cases. Second, we examined
the relationships of these molecules with VEGF and
microvascular characteristics, aiming to gain insight
into their potential involvement in the angiogenic process.
Third, we tested the correlation of these molecules with
p-JAK2 and the transcription factors p65/RelA (NFκB),
p-c-Jun (AP-1), HIF-1a, and p53 by Western immuno-
blotting or immunohistochemistry in a subset of cases.




This is a study of 118 patients with RCC (diagnosed
between 1996 and 2008) for whom archival primary
tumor material at diagnosis, prior to chemotherapy,
was available. In all cases, the histological diagnosis
and grading were peer-reviewed by two pathologists
(PK, AS) according to the principles laid down in the
World Health Organization classification [21]. This study
was approved by the University of Athens Medical School
Ethics Committee and informed consent was obtained
from each patient before study enrollment. The stage of
each tumor was assigned following the guidelines from
the 7th edition of TNM classification [22] and was known
for 106 patients: 28 patients had stage I and 15 had stage
II, 24 had stage III and 39 had stage IV disease. Follow-up
information was available for 94 patients. The characteris-
tics of patients enrolled in the present study are presented
in Table 1.
Table 1 Clinicopathological characteristics of 118 patients
enrolled in the present investigation





Clear cell RCC 99 (83.9%)
Papillary RCC 9 (7.63%)
















Not available 25 (21.2%)










Not available 57 (48.30%)
Follow-up
Alive/censored 43 (45.74%) Follow-up:
49 months (6-108.8 months)
Dead of disease 51 (54.26%) Follow-up:
30.37 months (1.77-117.43 months)
Median (range)
Age 61 (30-80)
*Other histological types include collecting duct carcinoma (1 case),
unclassified carcinoma (1 case), Chromophobe carcinoma with oncocytoma
(1 case) and multilocular cystic carcinoma (2 cases).
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Immunostaining was performed on paraffin-embedded
4 μm sections of formalin fixed tumor tissue using the two-
step peroxidase conjugated polymer technique (DAKO
Envision kit, DAKO, Carpinteria, CA). The primary anti-
bodies used are listed in Table 2. In negative controls pri-
mary antibodies were substituted with non-immune serum.
Evaluation of immunostained slides stained with IL-8,
IL-6, SOCS3, CXCR2, p65/RelA, HIF-1a, p53 and VEGF
was performed using light microscopy by two experienced
pathologists (PK, AS) without knowledge of the clinical
information and a Histo-score (H-score) based on the
percentage of neoplastic cells displaying cytoplasmic
immjunoreactivity multiplied by staining intensity was
calculated. p65/RelA, HIF-1a and p53 were assessed in
30 random cases, whereas the remaining antibodies in the
entire cohort. p-STAT3 nuclear staining and microvessel
characteristics were evaluated using computerized image
analysis software Image Pro software v5.1 (Media Cyber-
netics Inc.) on a Pentium III PC, as described previously
[23]. The stained slides for CD31 and anti-pSTAT-3 were
examined field by field at low magnification (×40 OLYM-
PUS BX51TF microscope) to identify the area showing
the most intense vascularisation (i.e. the “hot spot”) and
the highest H-score respectively. For CD31 the vascular
hot spot area was photographed at ×200 magnification
(OLYMPUS SC-30 Digital Camera) and stored as TIFF
image file (2048 × 1532 pixels, RGB, 24-bit). For each
countable microvessel several morphometric parameters
were automatically established: major axis length (i.e. the
distance between the two points along the vessel periphery
that are further apart), minor axis length (i.e. the longest
axis perpendicular to major axis formed by two points
along the vessel periphery), perimeter, area (luminal plus






( 4πareaperimeter2 ), compactness (
perimeter2
area ), MVD (microvessel dens-
ity, i.e. the total count of microvessels per optical field) and
TVA (total vascular area, i.e. the total area occupied by
microvessels). For each case the mean value of major and
minor axis length, area, perimeter, Feret diameter, shape
factor and compactness along with MVD and TVA were
recorded for statistical analysis. In cases where the most
vascularized area was not obvious, two or more optical
fields were photographed and the field with the highest
MVD was finally chosen for further analysis.
Western immunoblotting analysis
Western immunobloting analysis of IL-6, IL-8, CXCR2,
SOCS-3, p-STAT-3, p-JAK2 and p-c-Jun expression was
also performed on five RCC samples. After homogenization
and fractionation of fresh frozen tumor tissue, 100 μg
protein was separated on a 10% polyacrylamide gel
and blotted onto nitrocellulose membranes, probed with













IL-8 118 Polyclonal Invitrogen Corporation,
Camarillo, CA
AHC 0881 Rabbit Normal
tonsillar tissue
pH 6 (low) 1:50, 18 h 4°C
IL-6 118 Polyclonal Santa Cruz Biotechnology,
Santa Cruz, CA
SC 1265 Goat Normal
tonsillar tissue
pH 6 (low) 1:50, 18 h 4°C
SOCS-3 118 Polyclonal Santa Cruz Biotechnology,
Santa Cruz, CA
SC 9023 Rabbit Cholangiocarcinoma pH 6 (low) 1:100, 18 h 4°C
CXCR2 118 Monoclonal R&D Systems,
Abingdon, England
MAB 331 Mouse Normal
tonsillar tissue
pH 9 (high) 1:100, 18 h 4°C
VEGF 117 Monoclonal Pharmingen BD
Company, San Diego, CA
clone G153-
694
Mouse Glioblastoma pH 6 (low) 1:40, 18 h 4°C
p-STAT3 [specific
at site Tyr 705]
117 Monoclonal Cell Signaling Technology
Inc., Boston, MA, USA
D3A7 XP Rabbit Human
breast cancer
pH 6 (low) 1:100, 18 h 4°C
CD31 111 Monoclonal DAKO clone JC70A Mouse Kaposi sarcoma pH 9 (high) 1:20, 18 h 4°C
P53 30 Monoclonal DAKO IR616 Mouse Serous ovarian
carcinoma
pH 6(low) Pre-diluted, 1 h 37°C
HIF-1a 30 Monoclonal Neomarkers Inc.
Fremont CA, USA
MS 1164P Mouse Glioblastoma pH 6(low) Pre-diluted, 1 h 37°C
p65/RelA 30 Polyclonal Zymed laboratories Inc.,
California, USA
18-7308 Rabbit breast carcinoma pH 6(low) 1:300, overnight 37°C
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horseradish peroxidase (HRP)-conjugated goat-anti-rabbit
IgG or HRP-conjugated goat-anti-mouse IgG secondary
antibody (AP132P and AP124P respectively, Chemicon,
Millipore, Temecula, CA, USA). The same primary anti-
bodies described in Table 2 were used at the following
dilutions: 1:2,000 for anti–p-STAT-3, 1:200 for anti–SOCS-
3, anti-CXCR2, and anti-IL-6. The anti-IL-8 antibody was
diluted to a concentration of 0.1 μg/mL. The anti-p-JAK2
(sc-16566-R, Santa Cruz, 200 μg/ml) and anti-p-c-Jun
(sc-822, Santa Cruz, 200 μg/ml) were diluted at 1:200.
Bands were visualized using ECL chemiluminescence
detection reagents (Perkin Elmer, Athens, Greece). Relative
protein amounts were evaluated by a densitometric analysis
using Image J software (La Jolla, CA, USA) and normalized
to the corresponding Actin levels. All experiments have
been performed at least 3 times and representative results
of one experiment are shown.Statistical analysis
Statistical analysis was performed by a M.Sc. Biostatistician
(GL). In the basic statistical analysis IL-6, IL-8, SOCS-3,
CXCR2, VEGF, p65/RelA, HIF-1a, p53, p-STAT-3 ex-
pression and microvascular characteristics were treated as
continuous variables. Associations with clinicopathologi-
cal parameters and microvascular characteristics were
tested using non-parametric tests with correction for
multiple comparisons.
The set of microvascular parameters was subjected to
factor analysis using the principal component extractionmethod. Three factors were extracted. The first factor rep-
resented microvessel caliber encompassing area, perim-
eter, Feret diameter and major and minor axis length. The
second one represented microvessel shape (shape factor
and compactness), whereas the third one represented the
extent of microvascular network. The estimated factor
scores were used in multivariate survival analysis.
Survival analysis was performed using death by disease
as an endpoint. The effect of various clinicopathological
parameters on clinical outcome was assessed by plotting
survival curves according to the Kaplan-Meier method
and comparing groups using the log-rank test. Numerical
variables were categorized on the basis of cut-off values
provided by ROC curves. Multivariate analysis was per-
formed using stepwise forward Cox’s proportional hazard
estimation model. Power estimation of the log-rank tests
regarding SOCS3 and CXCR2 H-score was performed
using the Freedman method for estimation of censored
data. Statistical calculations were performed using the
Statistical package STATA 11.0 for Windows. All results
with a two-sided p level ≤0.05 were considered statistically
significant, whereas a p-value between 0.05 and 0.10 was
considered of borderline significance.Results
Western blot analysis
The expression levels by Western blot in the examined 5
cases were found to correlate with the immunohistochemical
expression of IL-6, IL-8, CXCR2, p-STAT-3 and SOCS-3
(Figure 1; Additional file 1: Figure S1-5).
Figure 1 IL-6, IL-8, CXCR2, SOCS-3 and p-STAT-3 protein
levels in fresh-frozen tissue specimens by Western blot and
immunohistochemical expression of CXCR2, SOCS-3 and IL-8
in formalin-fixed tissue from 2 representative cases (#1, 4:
Clear cell RCCs, #2: Papillary RCC, #3, 5: Chromophobe RCCs).
Detection of IL-6 (A), IL-8 (B) CXCR2 (C) SOCS-3 (D) and p-STAT-3
(E) in the 5 cases. Western immunoblotting validated the results
of immunohistochemistry.
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expression in RCC and correlation with clinicopathological
parameters
IL-6 and IL-8 expression were detected in 101/118 (85.6%)
and 58/118 (49.15%) cases with the H-score ranging from
1-300 and 0.01-100 respectively (Figure 1A, B; Additional
file 1: Figure S1, Additional file 2: Figure S2). CXCR2 was
expressed in 112/118 cases with the H-score ranging from
2-285 (median value in positive cases: 80) (Figure 1C;
Additional file 3: Figure S3). Immunoreactivity for all
three antibodies was localized in the cytoplasm of neo-
plastic cells, increasing around necrosis. Endothelial cells
and scattered macrophages displayed CXCR2 immunore-
activity which was also seen in the epithelial cells of dis-
tal proximal tubules and collecting ducts, albeit at lesser
intensity.
IL-6 and IL-8 were coexpressed in 52/118 (44.06%)
cases. Coexpression of IL-6 and CXCR2 was observed in
97/118 (82.2%) with only fifteen of CXCR2 positive cases
being negative for IL-6 (15/112, 13.4%). Coexpression of
IL-8 and CXCR2 was observed in 58/118 (49.15%) cases,
with a significant number of CXCR2 positive cases (54/112
48.2%) being negative for IL-8. The vast majority, however,
of these cases (45/54, 83.3%) expressed IL-6.
The correlations among the molecules under study are
shown in Table 3. A significant positive correlation emerged
between IL-6 and CXCR2 as well as between IL-8 and
CXCR2. The former relationship, however, lost its statistical
significance in a multivariate regression model including
VEGF. Moreover, IL-6 H-score was marginally higher in
the cases positive for IL-8.
The correlations between the molecules under study
and clinicopathological characteristics are shown in
Table 4. IL-8 expression levels were positively associated
with histological grade and tumor stage (Figures 2A and
3A), the former relationship being of borderline signifi-
cance. Accordingly, CXCR2 H-score increased in parallel
with histological grade and marginally with tumor stage
(Figure 2B and 3B). Interestingly, both IL-8 and CXCR2
H-scores were correlated with the presence (Figure 4A, B)
and the total number of metastases. All other relationships
of IL-6, IL-8 and CXCR2 H-score with clinicopathological
features were not significant.
Table 3 Correlations among IL-6, IL-8, CXCR-2, SOCS-3 and VEGF H-score in the entire cohort (Results of Spearman
correlation coefficient)
IL-6 IL-8 CXCR2 SOCS-3 p-STAT-3 VEGF
IL-8 NS*





SOCS-3 NS NS NS NS
p-STAT3 NS NS NS NS NS










*IL-6 H-score was marginally higher in the cases positive for IL-8 (Mann Whitney U test, p = 0.0992).
**This correlation failed to attain statistical significance in a multivariate model, including the presence of metastasis, to which both were significantly related.
***This relationship lost its statistical significance in a multivariate regression model including VEGF.
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expression in RCC and correlation with clinicopathological
parameters
SOCS-3 expression was cytoplasmic or membranous and
was detected in 111/118 (94.07%) cases (Figure 1D;
Additional file 4: Figure S4). p-STAT-3 expression was
nuclear and was recorded in 84/117 (71.79%) (Figure 1E;
Additional file 5: Figure S5). Endothelial and inflammatory
cells were also positive for SOCS3 and p-STAT-3 and
therefore served as internal positive controls. Weak
SOCS-3 expression was noted in distal tubules and
collecting ducts. Coexpression of SOCS-3 and p-STAT-3
was observed in 79/117 (67.52%) cases. SOCS-3 H-score
was marginally higher in the cases positive for p-STAT-3
(p = 0.0707).
SOCS-3 H-score was positively correlated with the
presence (Figure 4C) and the total number of metasta-
ses, as well as with disease progression. An inverse cor-
relation between p-STAT-3 H-score and histological grade
(Figure 2C), the presence (Figure 4D) and the total num-
ber of metastases was also established.
Relationship of IL-6, IL-8, SOCS-3, CXCR2 and p-STAT-3
expression with VEGF
VEGF H-score was positively correlated with IL-6, CXCR2
and IL-8, the latter relationship being of marginal signifi-
cance (Table 3). Interestingly, although SOCS-3 and VEGF
seemed to be positively correlated, when we adjusted a
multivariate model including VEGF and SOCS-3 H-score
along with the presence of metastasis, a parameter with
which both molecules were significantly correlated, the re-
spective relationship between VEGF and SOCS-3 failed to
attain statistical significance (Table 3).
Relationship of VEGF, IL-6, IL-8, SOCS-3, CXCR2 and
p-STAT3 expression with microvascular characteristics
The correlations among IL-6, IL-8, CXCR-2, SOCS-3
and VEGF H-score andmicrovascular characteristics are
shown in Table 5. Significant positive correlations emergedbetween VEGF H-score and microvessel area, TVA or Feret
diameter. Moreover, CXCR2 was inversely correlated with
major axis length, perimeter, area, minor axis length, Feret
diameter and compactness, the latter four correlations
being of marginal significance, whereas it was positively
correlated with shape factor. Furthermore, SOCS-3 H-score
increased in parallel with shape factor and was inversely
correlated with compactness. Although, IL-8 seemed to be
negatively correlated with MVD, when we adjusted a multi-
variate model including MVD and IL-8 H-score along with
histological grade, the respective relationship between these
two molecules failed to attain statistical significance.
Relationship of VEGF and microvascular characteristics
with clinicopathological features
VEGF was correlated with the presence of metastasis
(Figure 4E). Moreover, minor axis length was positively
correlated with histological grade (p = 0.0684, Figure 2D),
being marginally higher in grades III/IV. As expected,
clear cell carcinomas displayed higher MVD and TVA as
well as compactness (p = 0.0001 for MVD and TVA, and
p = 0.0147 for compactness) and lower levels of shape
factor (p = 0.0144) when compared to the remaining
histological types (Figures 5A-D and 6), consistent with
the much higher vascularity of clear cell RCC, as com-
pared to the remaining types [1,2]. The increased com-
pactness and lower shape factor values of microvessels in
clear cell RCC illustrate the presence of collapsed vessels
sections indicative of decreased intraluminal pressure
(according to Bernoulli’s law) and consequently enhanced
intratumoral blood flow [23].
Relationship of IL-6, IL-8, SOCS-3, CXCR2 with p65/RelA,
HIF-1a, p53, p-JAK2 kinase and p-c-Jun
SOCS-3 and CXCR2 were positively correlated with
HIF-1a (R = 0.3675, p = 0.0498 for SOCS-3 Figure 7A
and R = 0.9050, p < 0.0001 for CXCR2, Figure 7D), p65/
RelA (R = 0.6204, p = 0.0003 for SOCS-3 Figure 7B and
R = 0.8069, p < 0.0001 for CXCR2, Figure 7E) and p53
Table 4 Associations of the molecules under study with clinicopathological parameters (NS: not significant)














Histological type NS NS NS NS NS NS
Clear cell 99 20 (0-300) 0 (0-100) 80 (0-285) 60 (0-300) 4.5 (0-257) 127.5 (0-300)
Papillary 9 30 (0-270) 0 (0-25) 140 (0-270) 75 (0-285) 24 (0-202) 120 (0-200)
Chromophobe 5 135 (10-180) 1.5 (0-45) 15 (0-160) 22.5 (0-190) 1 (0-52) 100 (20-180)
Other 5 60 (0-300) 1 (0-20) 20 (2-80) 22.5 (0-130) 0 (0-244) 120 (30-120)
Histological grade NS 0.0552 0.0126 NS 0.0325 NS
I/II 52 52.5(0-300) 0 (0-45) 65 (0-237.5) 38.75 (0-285) 46 (0-257) 127.5 (0-300)
III/IV 66 15 (0-300) 0.35 (0-100) 90 (0-285) 67.5 (0-300) 1 (0-205) 120 (0-300)
Stage NS 0.0141 0.0703 NS NS NS
Ι/II 43 30 (0-300) 0(0-45) 45(0-270) 37.5 (0-285) 33 (0-244) 97.5 (1.5-300)
ΙΙI/IV 63 20 (0-300) 0.75(0-100) 80 (0-285) 60 (0-300) 1 (0-257) 120 (0-300)
Presence of metastasis NS 0.0099 0.0001 0.0155 0.0426 0.0371
Absence 30 30 (0-300) 0 (0-45) 20 (0-270) 20 (0-160) 44.5 (0-244) 90 (0-250)
Presence 64 17.5 (0-300) 0.5 (0-100) 95 (0-285) 75 (0-300) 1 (0-257) 135 (5-300)
Disease progression NS NS NS 0.0401 NS NS
Absence 19 20 (0-200) 0.75 (0-10) 120 (16-270) 50 (0-180) 1 (0-257) 140 (10-300)
Presence 42 12.5 (0-300) 0.75 (0-100) 90 (0-285) 95 (205-300) 10(0-207) 145 (5-300)
Total number of metastases 94 R = 0.3458, p = 0.0006 R = 0.3333, p = 0.0010 NS R = 0.2945, p = 0.0040 R = -0.2212, p = 0.0331 NS

















Figure 2 Box plots illustrating the correlations between IL-8 (A), CXCR-2 (B), p-STAT-3 (C) H-score and minor axis length (D) with
histological grade.
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0.8254, p < 0.0001 for CXCR2, Figure 7F) H-score. The
correlations between IL-6 or IL-8 with p65/RelA, HIF-1a,
p53 were not significant (p > 0.10).
Furthermore, Western blot analysis of 5 RCC cases
revealed that increased expression of SOCS-3 was associ-
ated with decreased p-JAK2 and p-c-Jun expression and
vice versa (Figure 8).Survival analysis
The results of univariate survival analysis are presented
in Table 6. The parameters adversely affecting survival
were advanced stage, increased CXCR2 (Figure 9A) and
SOCS-3 (Figure 9B) and decreased p-STAT-3 (Figure 9C)
H-score although the latter relationship was of marginal
significance. The comparison of survival functions among
the groups allocated by CXCR2 and SOCS3 H-score had a
statistical power of 0.84 and 0.96 respectively at a signifi-
cance level of 0.05.The results of multivariate survival analysis are pre-
sented in Table 7. SOCS-3 H-score emerged as an in-
dependent predictor of adverse prognosis, along with
tumor stage.Discussion
The angiogenic properties of Th2 cytokines (IL-6 and
IL-8) have led to the inevitable conclusion that they may
potentiate RCC growth, metastasis and immune evasion
[2,24]. Despite experimental evidence implicating IL-8/
CXCR2 axis and SOCS-3 in the progression of RCC,
in situ characterization of their expression by RCC
cells and its clinical relevance has not thus far been
performed.
We herein describe for the first time the cytoplasmic
immunolocalization of CXCR2 in neoplastic cells in the
vast majority of our RCC cases, along with IL-6 and IL-8,
disputing previously reported findings in a small series
[20]. Our findings concur with the reported identification
Figure 3 Box plots illustrating the correlations between IL-8 (A) and CXCR-2 (B) H-score with stage.
Figure 4 Box plots illustrating the correlations between IL-8 (A), CXCR-2 (B), SOCS-3 (C), p-STAT-3 (D) and VEGF (E) H-score with the
presence of metastases.
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Table 5 Correlations between IL-6, IL-8, CXCR-2, SOCS-3 and VEGF H-score and microvascular characteristics (Results of
Spearman correlation coefficient)








IL-6 NS NS NS NS NS NS NS NS NS
IL-8 R = -0.1873,
p = 0.0432**
NS NS NS NS NS NS NS NS


















pSTAT3 NS NS NS NS NS NS NS NS NS
VEGF NS R = 0.2166,
p = 0.0230
NS NS R = 0.1967,
p = 0.0394




*When analysis was performed on a categorical basis SOCS-3 H-score was significantly correlated with shape factor (Mann Whitney U test, p = 0.0286).
**This relationship failed to attain statistical significance in a multivariate model including MVD and IL-8 H-score along with histological grade, the latter emerging
as a confounder in the correlation between these two molecules.
Figure 5 Box plots illustrating the correlations between MVD (A), TVA (B), shape factor (C) and compactness (D) with histological type.
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Figure 6 Immunohistochemical staining of a clear cell (A) and a chromophobe (B) RCC. (C, D) Same fields as in (A, B). The outline of each
vessel is traced; the red layer represents the section area of each vessel. Clear cell RCC (A, C) displays clearly higher MVD and TVA when
compared to chromophobe RCC (B, D).
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http://www.biomedcentral.com/1471-2407/14/149of CXCR2 mRNA and protein in the RCC cell line A-498
and in short term primary RCC cell cultures [25]. It is
conceivable that such a widespread CXCR2 expression by
the neoplastic cells could be attributed to HIF-1a, which is
known to be constitutively active in RCC driving theFigure 7 Plots illustrating the correlations of SOCS-3 and CXCR2 with
SOCS-3 with p65/RelA, HIF-1a and p53. (D, E, F) CXCR2 with p65/RelA, HIF-1acquisition of a hypoxic phenotype or to other hypoxia –
inducible transcription factors [26,27]. To address this
issue, we investigated the relationship between CXCR2
and HIF-1a, p53 or p65/RelA expression in a subset of
RCC specimens. We verified that CXCR2 (but not IL-8)p65/RelA, HIF-1a and p53 in the 30 cases analyzed. (A, B, C)
a and p53.
Figure 8 Expression of CXCR2, SOCS-3, p-JAK-2 and p-c-Jun in 5 cases. Western immunoblotting of CXCR2, SOCS-3, p-JAK2 and p-c-Jun
expression in 5 tumor cases (A). Densitometric analysis of relative protein amounts normalized to the corresponding Actin levels was performed
using Image J software (B).
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http://www.biomedcentral.com/1471-2407/14/149and these transcription factors are strongly interrelated,
although the underlying mechanisms remain to be dec-
iphered. For example, computational analysis has iden-
tified potential binding sites for HIF-1a and NF-κB in
CXCR2 promoter in hypoxic prostate cancer cells [28]
and p53 reportedly upregulates CXCR2 transcription
by binding to CXCR2 promoter [29]. The increased
Western blot levels of p-c-Jun we observed in RCC are
also consistent with the reported decreased levels of c-Jun
N-terminal kinase in CXCR2 knock-out mice [30]. The
observed relationship between CXCR2 and VEGF in our
series probably reflects the fact that they are both tran-
scriptional targets of HIF-1a [27,28].
We also documented a liaison between CXCR2 and
IL-8. Interestingly, 83.3% of CXCR2 positive/IL-8 negative
cases exhibited IL-6 immunoreactivity, implying a re-
dundancy of the angiogenic mechanisms in this tumor
[31]. Both IL-8 and CXCR2 expression increased along
with Fuhrman’s grade and stage advocating that IL-8/
CXCR2 autocrine signaling underpins both the develop-
ment and the progression of RCC and represents a
mechanism adopted by diverse tumor types to augment
their angiogenic, growth and metastatic potential [32].
On the contrary, IL-6 showed no association with grade
or stage in our series.
A major finding is that IL-8/CXCR2 signaling may
be implicated in the metastatic process of RCC, since
their expression levels were correlated with the pres-
ence and/or number of metastases in our series. Sev-
eral lines of in vitro and in vivo evidence corroborate
this notion. First, IL-8 levels positively correlated with
matrix metalloproteinases, which facilitate the meta-
static process by degrading basement membranes rev.
in ref [1]. Second, IL-8 tissue levels are reportedly
higher in metastatic RCC [1]. Third, increased levels
of CXCR2 have been recorded in endothelial cells of
metastatic RCC [20]. Fourth, orthotopic RCC tumorsdisplayed a reduced growth and metastatic potential in
CXCR2 -/- mice [20].
It is of interest that CXCR2, but not IL-8 was associated
with the presence of small caliber microvessels as well
as with high values of shape factor corresponding to
the presence of rounder vessel sections. This particular
pattern of microvessels denotes an increase in intralum-
inal pressure because of retarded intratumoral blood flow
within an abnormal vascular network [33].
Although CXCR2 expression was predictive of poor
patient survival in univariate analysis, this effect did not
hold true in multivariate analysis. Interestingly, IL-8 was
not prognostically informative obviously indicating that
CXCR2, representing the point of convergence of all
ELR + chemokines may provide a more accurate estimate
of tumors’ angiogenic or invasive potential than any
individual chemokine upstream [34]. In this context,
blockade or silencing of CXCR2 gene attenuated human
pancreatic tumor growth [35] and arrested ovarian carcin-
oma cells at G0/G1 and G2/M [36]. Furthermore, CXCR2
has been shown to suppress the expression of proapop-
totic factors while enhancing the expression of anti-
apoptotic proteins [35], thereby assisting neoplastic cells
to resist chemotherapy.
An intriguing observation in our study is that p-STAT-3
inversely correlated with grade, the presence and number
of metastases and marginally with survival. This ap-
parently disagrees with experimental studies in which
transfection of dominant-negative STAT-3 completely
abolishes the anti-apoptotic effect of IL-6 on RCC cells
[37], but also with an early report implicating the con-
stitutive activation of STAT-3 in the metastatic potential
of RCC cells in a small series [38]. Such conflicting data
reflects the dual role of STAT-3 harboring both tumor
suppressive and oncogenic properties [23,39].
To the best of our knowledge, our study is the first to
deal with the expression of SOCS-3 in RCC tissue samples.
Table 6 Results of Univariate survival analysis (log-rank test)
Variables Log-rank test (p-value)
Age
<61 vs ≥61 years 0.1142
Gender
Male vs Female 0.5701
Histological type
Clear cell vs non- clear cell 0.2441
Histological grade
I/ II vs III/IV 0.2378
Stage
I/II vs III/IV 0.0002
Total number of metastases
1 vs more 0.2787
IL-6 H-score
<24 vs ≥24 0.8718
IL-8 H-score
Negative vs positive 0.1311
CXCR2 H-score
<80 vs ≥80 0.0293
SOCS3 H-score
<60 vs ≥60 0.0478
p-STAT3 H-score
<4 vs ≥4 0.0730
VEGF H-score
<120 vs ≥120 0.8804
MVD
<125 vs ≥125 0.9391
TVA
<30069.62 vs ≥30069.62 0.2134
Area
<222.345 vs ≥222.345 0.1057
Major axis length
<24.771 vs ≥24.771 0.4925
Minor axis length
<9.541 vs ≥9.541 0.3642
Perimeter
<74.329 vs ≥74.329 0.1194
Shape factor
< 0.495 vs ≥0.495 0.3118
Feret diameter
<16.826 vs ≥16.826 0.1057
Compactness
<25.361 vs ≥25.361 0.2241
Bold signifies a statistically significant result.
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http://www.biomedcentral.com/1471-2407/14/149Given that SOCS-3 is a negative regulator of STAT-3
activation, it was initially believed that it might function as
a tumor suppressor and, hence, its expression might be re-
pressed in neoplasms, particularly those with constitutive
activation of STAT-3. Our findings, however, fail to con-
firm this assumption, documenting SOCS-3 expression
in the vast majority of RCC cases mostly accompanied
by p-STAT-3 expression. We also failed to establish the
expected negative correlation between SOCS-3 and p-
STAT-3 in line with observations in other tumors [40,41].
The simultaneous presence of the two molecules in most
RCC specimens is consistent with the notion that SOCS-3
is a transcriptional target of STAT-3 [19]. Alternatively, it
could be hypothesized that neoplastic cells have developed
strategies to by-pass negative regulation by SOCS-3 [40].
However, increased SOCS-3 levels were accompanied by
decreased p-JAK-2 in Western blotting providing evidence
for the operation of the negative feedback loop between
SOCS-3 and JAK-2 signaling in RCC. Furthermore, in-
creased SOCS-3 expression was found to correlate with
reduced phosphorylation of c-Jun thus suggesting a pos-
sible suppression of AP-1 activity in RCC. In agreement
with our finding endogenous SOCS-3 has been reported
to block c-Jun phosphorylation and inhibit AP-1 activity
in neuroblastoma cells [42]. Furthermore, we were able
to elicit strong positive correlations between SOCS-3
and HIF-1a, p65/RelA and p53 in RCC recapitulating
recently published evidence that HIF-1a functions as an
important regulator of SOCS-3 in glioma cells [43] and
that SOCS-3 overexpression enhances p53 phosphoryl-
ation in pleural mesothelioma cells by inhibiting its deg-
radation [44].
One of the most important findings of the present in-
vestigation is the association of SOCS-3 expression with
the presence and number of metastases, progression and
diminished survival in RCC patients. It should be stressed
that the adverse prognostic significance of SOCS-3 was
maintained in multivariate survival analysis in the pres-
ence of stage, IL-6, IL-8, CXCR2, VEGF and microvascular
factor scores. Taking into account the low expression of
SOCS-3 in normal kidney, these findings bring forward
SOCS-3 as a tumor promoter in RCC, endowing neo-
plastic cells with a survival advantage. In harmony with
this assumption, SOCS-3 expression has been shown to
increase during development and progression of prostate
cancer [45] and enhances glioblastoma cell survival, its
loss converting the anti-apoptotic function of STAT-3
into pro-apoptotic [46]. A recent study has augmented
interest in SOCS-3 implicating it in the resistance to
IFN treatment in RCC [47]. Thus, overexpression of
SOCS-3 via gene transfection in IFN-sensitive RCC cells
significantly diminished the growth inhibitory effect of
IFN-α, Suppression of SOCS-3 by siRNA restored sensi-
tivity in IFN-α resistant RCC cells and suppressed the
Figure 9 Kaplan-Meier curves for cancer specific survival according to CXCR-2 (A), SOCS-3 (B) and p-STAT-3 (C) immunoexpression.
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http://www.biomedcentral.com/1471-2407/14/149growth of IFN-α resistant RCC xenograft [47], as well as
of 786-O RCC cell line following the combined adminis-
tration of anti-IL-6R and IFN-α [48].Conclusions
In summary, this is the first study highlighting the import-
ance of SOCS-3 overexpression into RCC progression,
metastatic process and biologic aggressiveness. More im-
portantly, our data stands in favor of SOCS-3 as an inde-
pendent prognostic marker and lays the ground for its
therapeutic targeting in combination with IFN-α. IL-8/
CXCR2 autocrine signaling also contributes to the angio-
genic and metastatic phenotype of RCC cells, but may be
of lesser importance as a therapeutic tool, although its tar-
geting might augment the therapeutic benefit gained from
SOCS-3 modulation and IFN-α treatment. Both CXCR2
and SOCS-3 appear to elaborate relationships with several
transcription factors induced under hypoxia, such as HIF-
1a, NF-κΒ, p53 and p-c-Jun. These findings should await
validation in prospective studies enrolling a larger number
of patients and allowing for subgroup analysis.Table 7 Cox proportional Hazards model with stepwise
forward selection for the 94 patients with RCC
HR P value 95% confidence interval of HR
SOCS3 H-score 1,004 0,045 1,000 1,008
Tumour stage 1,734 <0.001 1,277 2,355
IL-8, IL-6, CXCR2, SOCS-3, p-STAT3, VEGF, Microvascular factors and tumor
stage were introduced into the model.Additional files
Additional file 1: IL-6 protein levels in fresh-frozen tissue specimens
by Western blot and immunohistochemical expression of IL-6 in
formalin-fixed tissue in the same five cases (#1, 4: Clear cell RCCs, #2:
Papillary RCC, #3, 5: Chromophobe RCCs). Western immunoblotting
validated the results of immunohistochemistry.
Additional file 2: IL-8 protein levels in fresh-frozen tissue specimens
by Western blot and immunohistochemical expression of IL-8 in
formalin-fixed tissue in the same five cases (#1, 4: Clear cell RCCs, #2:
Papillary RCC, #3, 5: Chromophobe RCCs). Western immunoblotting
validated the results of immunohistochemistry.
Additional file 3: CXCR2 protein levels in fresh-frozen tissue
specimens by Western blot and immunohistochemical expression
of CXCR2 in formalin-fixed tissue in the same five cases (#1, 4: Clear
cell RCCs, #2: Papillary RCC, #3, 5: Chromophobe RCCs). Western
immunoblotting validated the results of immunohistochemistry.
Additional file 4: SOCS-3 protein levels in fresh-frozen tissue
specimens by Western blot and immunohistochemical expression
of SOCS-3 in formalin-fixed tissue in the same five cases (#1, 4: Clear
cell RCCs, #2: Papillary RCC, #3, 5: Chromophobe RCCs). Western
immunoblotting validated the results of immunohistochemistry.
Additional file 5: p-STAT-3 protein levels in fresh-frozen tissue
specimens by Western blot and immunohistochemical expression
of p-STAT-3 in formalin-fixed tissue in the same five cases (#1, 4:
Clear cell RCCs, #2: Papillary RCC, #3, 5: Chromophobe RCCs).
Western immunoblotting validated the results of immunohistochemistry.
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